Literature DB >> 22425356

Update on totally implantable venous access devices.

Ahmad Zaghal1, Mohamed Khalife, Deborah Mukherji, Nadim El Majzoub, Ali Shamseddine, Jamal Hoballah, Gabriele Marangoni, Walid Faraj.   

Abstract

The use of totally implantable venous devices (TIVAD) has changed the care and quality of life for cancer patients, these devices allow chemotherapy administration, and blood sampling without the need for repeated venipuncture. These ports are used mainly when IV access is needed only intermittently over a long period of time. We are presenting a brief overview on TIVADs, with focus on the mid and long-term complications associated with these devices with their management.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22425356     DOI: 10.1016/j.suronc.2012.02.003

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  20 in total

1.  Improving cancer patients' knowledge about totally implantable access port: a randomized controlled trial.

Authors:  Michela Piredda; Valentina Biagioli; Diana Giannarelli; Daniele Incletoli; Francesca Grieco; Massimiliano Carassiti; Maria Grazia De Marinis
Journal:  Support Care Cancer       Date:  2015-07-24       Impact factor: 3.603

2.  [Arterial malpositioning of a port catheter].

Authors:  H Dralle; K Kols; A Agha; M Sohn; I Gockel; M Lainka
Journal:  Chirurg       Date:  2019-02       Impact factor: 0.955

3.  Evaluation of the perceptions and cosmetic satisfaction of breast cancer patients undergoing totally implantable vascular access device (TIVAD) placement.

Authors:  Gabriel Liberale; Michel El Houkayem; Claire Viste; Fikri Bouazza; Michel Moreau; Issam El Nakadi; Isabelle Veys
Journal:  Support Care Cancer       Date:  2016-08-05       Impact factor: 3.603

4.  Ultrasound-guided vein puncture versus surgical cut-down technique in totally implantable venous access devices (TIVADS): a prospective comparative study on safety, efficacy andcomplications.

Authors:  Giuseppe Cavallaro; Alessandro Sanguinetti; Olga Iorio; Giuseppe D'Ermo; Andrea Polistena; Nicola Avenia; Gianfranco Silecchia; Giorgio De Toma
Journal:  Int Surg       Date:  2014 Jul-Aug

5.  Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion.

Authors:  Matthias Gabriel; Kerstin Niederer; Holger Frey
Journal:  J Vis Exp       Date:  2016-08-15       Impact factor: 1.355

6.  Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients.

Authors:  Ahmed El-Balat; Iryna Schmeil; Thomas Karn; Uwe Holtrich; Loreta Mavrova-Risteska; Achim Rody; Aly Youssef; Lars C Hanker
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

7.  Insertion of totally implantable central venous access devices by surgeons.

Authors:  Hyeonjun An; Chun-Geun Ryu; Eun-Joo Jung; Hyun Jong Kang; Jin Hee Paik; Jung-Hyun Yang; Dae-Yong Hwang
Journal:  Ann Coloproctol       Date:  2015-04-30

8.  Morbidity of chemotherapy administration and satisfaction in breast cancer patients: a comparative study of totally implantable venous access device (TIVAD) versus peripheral venous access usage.

Authors:  Kul Ranjan Singh; Gaurav Agarwal; Gitika Nanda; Gyan Chand; Anjali Mishra; Amit Agarwal; Ashok K Verma; Saroj K Mishra; Puneet Goyal
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

9.  Complications and management strategies of totally implantable venous access port insertion through percutaneous subclavian vein.

Authors:  Yusuf Velioğlu; Ahmet Yüksel; Emrah Sınmaz
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-10-23       Impact factor: 0.332

10.  Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli.

Authors:  Jui-Feng Hsu; Hsu-Liang Chang; Ming-Ju Tsai; Ying-Ming Tsai; Yen-Lung Lee; Pei-Huan Chen; Wen-Chieh Fan; Yu-Chung Su; Chih-Jen Yang
Journal:  World J Surg Oncol       Date:  2015-09-30       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.